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Despite recent advances, the treatment of 
brain diseases and neurological disorders, 
such as the Parkinson and Alzheimer syn-
dromes, multiple sclerosis, brain cancer, 
psychiatric disorders, many forms of epi-
lepsy, chronic pain, and migraine, remains 
a major challenge. There is a growing need 
for the development of effective CNS-active 
drugs that are able to reach the desired 
regions of the brain. This has proven to 
be problematical, as the brain is protected 
very effectively against exogenous sub-
stances, including many potentially useful 
CNS-active drugs. This issue has been dis-
cussed in detail at a EU-COST Exploratory 
Workshop which produced a policy paper 
for the EU (Kapitulnik et al., 2010).
Access to brain tissue and ensuing effects 
of drugs or other chemicals are dependent 
on their ability to cross the blood–brain bar-
rier (BBB; Pelkonen et al., 2008; Kapitulnik 
et al., 2009). The BBB is a physical and func-
tional barrier that prevents the entrance 
of many drugs and chemicals into brain 
cells regardless of their molecular size. The 
BBB controls access to the brain of essen-
tial nutrients, vitamins and ions, as well as 
some proteins and peptides, and removes 
the products of metabolism in the brain, 
for example neurotransmitter metabolites. 
It also prevents entry of potentially harmful 
substances into the brain (e.g., bilirubin, an 
endogenously formed neurotoxic catabolite 
of heme, as well as exogenous toxins).
The BBB comprises the endothelial 
cells of small blood vessels. The fact that 
endothelial cells of brain capillaries differ 
greatly from those in the periphery confers 
on the BBB its discriminatory character-
istics. Brain endothelial cells display tight 
junctions, absence of intercellular clefts 
and fenestrations, minor pinocytic activ-
ity, and a high electrical resistance. These 
cells have a continuous basal membrane 
and are surrounded by pericytes and the 
end feet of astrocytes, which are part of the 
BBB and control its permeability (reviewed 
by Abbott et al., 2010).
Proteins involved in drug transport 
(drug transporters, DTs) and metabolism 
(drug metabolizing enzymes, DMEs) have 
been described in many organs (liver, lung, 
kidney, intestine, brain, skin, blood vessels, 
and others). These proteins play important 
roles by governing both the traffic between 
organs and elimination of drugs and foreign 
compounds (xenobiotics), as well as in both 
synthesis and degradation/elimination of 
endogenous compounds (endobiotics) such 
as hormones and prostanoids. In certain 
instances, their action is beneficial (detoxifi-
cation of both xenobiotics and endobiotics), 
but they may also display deleterious effects, 
as is the case with certain DTs which do not 
allow drugs to enter the brain or DMEs that 
activate xenobiotics (e.g., drugs and chemi-
cal carcinogens) to form toxic metabolites 
(for detailed reviews see Dutheil et al., 2010; 
Miller, 2010). Some of the genes that regu-
late the expression of DTs and DMEs have 
been shown to be polymorphic, resulting 
in the synthesis of proteins with impaired 
or increased activities (Ieiri et al., 2009; 
Cascorbi and Haenisch, 2010; Franke et al., 
2010; Johansson and Ingelman-Sundberg, 
2011). These polymorphisms may thus pro-
foundly affect the blood levels of drugs and 
chemical toxins.
Drug transporters and DMEs are also 
present in the BBB. Using transcriptomics 
and proteomics approaches, the presence 
of these proteins has been demonstrated 
in isolated human brain microvessels and 
cortex biopsies (Shawahna et al., 2011). DTs 
and DMEs control the access to the brain 
and local concentration of both endobiotics 
and xenobiotics. Transport proteins enable 
passage of those substances required by 
the CNS, such as glucose, essential amino 
acids, and neurotransmitter precursors. 
There are also transporters and metabolic 
enzymes that function in the opposite direc-
tion, thereby preventing access to the brain 
of some lipid-soluble drugs and potentially 
toxic substances, including metabolites, 
which might otherwise be able to diffuse into 
the brain and cause damage. Unfortunately, 
this means that the BBB can also prevent 
otherwise effective drugs from entering the 
brain. It may also hinder side effects of these 
and other drugs. The number of these drugs 
is larger than once thought.
Moreover, the function of the DTs at 
the BBB is also affected during disease 
(Zlokovic, 2008; Engelhardt and Sorokin, 
2009), resulting in enhanced exposure of the 
CNS to neurotoxic compounds and reduced 
drainage of CNS-born proteins such as 
amyloid proteins, thus promoting neuro-
degeneration. Today we still know very lit-
tle about how inflammatory components 
of systemic or CNS diseases influence drug 
transport into the brain, and how peptides 
and proteins are taken across the BBB.
The importance of active transporters 
and local metabolism in the BBB in causing 
harmful effects of drugs and environmen-
tal chemicals remains largely unknown. 
Transporters and enzymes are known to 
work in conjunction with each other (e.g., 
in the intestine and liver; Benet, 2009), but 
it is not known how they are coordinated 
at the BBB, or how important enzymes are 
relative to transporters at the BBB. Thus it 
is of utmost importance to characterize the 
expression, activity and physiological and 
pathological regulation of these proteins 
in the BBB and adjacent brain areas, both 
in vivo and in model systems.
The methods currently used to study 
the transport and metabolism of drugs 
and toxins in the BBB and adjacent brain 
areas include a battery of probes for 
measuring the expression of transporter 
and enzyme genes in appropriate in vitro 
and in vivo model systems, a battery of 
substrate probes for various transporters 
and  xenobiotic-metabolizing enzymes to 
be studied in the model systems, immu-
nochemical techniques for studying the 
localization and architecture of transport-
ers and enzymes in brain structures, and 
imaging techniques to investigate time- 
and site-dependent  processes of transport 
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and metabolism. Basic characterization 
of all developed model systems with the 
help of the above mentioned methods is 
a necessary prerequisite for the extensive 
application of the models for other types 
of studies. Moreover, development of 
new models and methods is also of prime 
importance.
Future challenges
1. Although important knowledge on DTs 
in blood–brain and blood–CSF inter-
faces has accumulated during the last 
decade, it is still very limited. However, 
it is becoming clear that the battery 
of DTs expressed in these interfaces is 
somewhat different than in periphe-
ral organs, thus making it necessary to 
carefully identify the DTs in the above 
interfaces as well as understanding 
their regulation and function.
2. The available knowledge on DMEs in 
these interfaces is rather limited, and 
it is thus imperative to further study 
which are the enzymes expressed in 
these tissues.
3. Given the known interplay between 
DTs and DMEs in liver and intestine, 
it is important to determine if these 
proteins work in tandem in the CNS or 
compete for their substrates.
The results of studies on the interac-
tions between enzymes and transport-
ers, and between drugs and endogenous 
 compounds, as well as on the role of enzyme 
and transporter polymorphisms in deter-
mining brain access and active site con-
centration of drugs, will contribute to the 
therapeutic impact of existing and newly 
designed CNS drugs, as well as to the pre-
vention of the toxic effects of xenobiotics.
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